Oncology
HBM contact: Dr Ivo Staijen, Dr Chandra P. Leo
Company status: public
Monte Rosa Therapeutics is a biotechnology company
developing molecular glues to degrade disease-causing proteins. The company has
developed a platform to rationally design small molecules that reprogram
ubiquitin ligases to eliminate disease drivers previously deemed undruggable.